Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Multi-centre, Double-blind, Placebo-controlled Parallel Group Study to Assess the pharmacoMRI Effects of AZD6765 in Male and Female Subjects Fulfilling the Criteria for Major Depressive Disorder
Brief Summary: The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in depressed subjects.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Intranasal Esketamine 84mg plus Oral Antidepressant; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Drug: Duloxetine (Oral Antidepressant), Drug: Escitalopram (Oral antidepressant), Drug: Sertraline (Oral Antidepressant), Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant) | Arm Label: Esketamine 56 mg plus Oral Antidepressant; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Drug: Duloxetine (Oral Antidepressant), Drug: Escitalopram (Oral antidepressant), Drug: Sertraline (Oral Antidepressant), Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant) | Arm Label: Placebo plus Oral Antidepressant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Duloxetine (Oral Antidepressant), Drug: Escitalopram (Oral antidepressant), Drug: Sertraline (Oral Antidepressant), Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant) | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Esketamine 56 mg plus Oral Antidepressant, Intranasal Esketamine 84mg plus Oral Antidepressant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus Oral Antidepressant | Intervention Type: DRUG; Name: Duloxetine (Oral Antidepressant); Assigned to Arm(s): Esketamine 56 mg plus Oral Antidepressant, Intranasal Esketamine 84mg plus Oral Antidepressant, Placebo plus Oral Antidepressant | Intervention Type: DRUG; Name: Escitalopram (Oral antidepressant); Assigned to Arm(s): Esketamine 56 mg plus Oral Antidepressant, Intranasal Esketamine 84mg plus Oral Antidepressant, Placebo plus Oral Antidepressant | Intervention Type: DRUG; Name: Sertraline (Oral Antidepressant); Assigned to Arm(s): Esketamine 56 mg plus Oral Antidepressant, Intranasal Esketamine 84mg plus Oral Antidepressant, Placebo plus Oral Antidepressant | Intervention Type: DRUG; Name: Venlafaxine Extended Release (XR) (Oral Antidepressant); Assigned to Arm(s): Esketamine 56 mg plus Oral Antidepressant, Intranasal Esketamine 84mg plus Oral Antidepressant, Placebo plus Oral Antidepressant
C: Arm Label: AXS-05; Type: EXPERIMENTAL; Interventions: Drug: AXS-05 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AXS-05; Assigned to Arm(s): AXS-05 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Propofol

Answer: A